Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
J Clin Invest
; 130(12): 6409-6416, 2020 12 01.
Article
in En
| MEDLINE
| ID: mdl-32809969
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Purines
/
Pyrazoles
/
Sulfonamides
/
Azetidines
/
Off-Label Use
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Aspects:
Ethics
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Clin Invest
Year:
2020
Document type:
Article